HC Wainwright Issues Optimistic Estimate for ARTV Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Investment analysts at HC Wainwright upped their Q2 2026 earnings per share estimates for shares of Artiva Biotherapeutics in a research report issued to clients and investors on Friday, May 8th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.80) per share for the quarter, up from their prior forecast of ($0.94). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($3.33) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.67) EPS, FY2027 earnings at ($3.50) EPS, FY2028 earnings at ($4.52) EPS, FY2029 earnings at ($2.56) EPS and FY2030 earnings at $0.00 EPS.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07).

Several other equities analysts also recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Cantor Fitzgerald upped their price objective on Artiva Biotherapeutics from $10.00 to $40.00 and gave the company an “overweight” rating in a research note on Monday. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Monday, May 4th. Wall Street Zen upgraded Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Wedbush upped their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Artiva Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $33.25.

Artiva Biotherapeutics Stock Down 2.7%

Shares of NASDAQ ARTV opened at $10.60 on Tuesday. Artiva Biotherapeutics has a twelve month low of $1.47 and a twelve month high of $14.53. The stock’s 50 day moving average price is $7.81 and its 200-day moving average price is $5.43. The company has a market capitalization of $262.03 million, a PE ratio of -2.99 and a beta of 2.86.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC lifted its position in shares of Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after acquiring an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Artiva Biotherapeutics by 46.8% during the fourth quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock worth $498,000 after acquiring an additional 37,053 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Artiva Biotherapeutics during the fourth quarter worth $341,000. Finally, Jane Street Group LLC purchased a new stake in shares of Artiva Biotherapeutics during the second quarter worth $67,000.

Artiva Biotherapeutics News Roundup

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Cantor Fitzgerald lifted its price target on Artiva Biotherapeutics to $40 and kept an overweight rating, signaling strong upside potential. Cantor Fitzgerald Issues Positive Forecast for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price
• Positive Sentiment: Wedbush also raised its target to $40 and maintained an outperform rating, reinforcing bullish sentiment around the stock. Wedbush Issues Positive Forecast for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price
• Neutral Sentiment: HC Wainwright increased FY2026, Q2 2026, Q3 2026, Q4 2026, and FY2030 EPS estimates, suggesting improving earnings visibility. HC Wainwright estimate updates for Artiva Biotherapeutics
• Negative Sentiment: HC Wainwright lowered FY2027, FY2028, and FY2029 EPS estimates, which tempers the longer-term optimism. HC Wainwright estimate revisions for Artiva Biotherapeutics

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.